Overview

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Johns Hopkins University
Treatments:
Fluorodeoxyglucose F18
Gemcitabine